# **Open Access**



# Primary adrenal insufficiency and myocarditis in COVID-19 disease: a case report

Delaram Eskandari<sup>1\*</sup>, Amir Ziaee<sup>1</sup>, Abdollah Amirfarhangi Anbardan<sup>1</sup>, Elahe Zeinali<sup>1,2</sup> and Atefe Tirkan<sup>1,3</sup>

# Abstract

**Background:** COVID-19 has different manifestations from respiratory to GI problems, and some of them are more common, but some are rare. Reporting rare cases can significantly advance our understanding of the disease.

**Case presentation:** In this case, we report an 18-year-old teenage boy with chest pain and resistant hypotension following COVID-19 infection, finally diagnosed as primary adrenal insufficiency and COVID-19 myocarditis.

**Conclusion:** Adrenal insufficiency can be life-threatening due to its adverse effects on hemodynamic and electrolyte equilibrium. In addition, COVID-19 induced myocarditis can make the situation more complicated.

Keywords: COVID-19, Primary adrenal insufficiency, Myocarditis, Case report

# Background

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) or COVID-19 (coronavirus disease-19) has endangered millions of lives worldwide and is progressing rapidly day by day. To date, more than 169.5 individuals have been infected with COVID-19 and 3.5 million have died due to its complications [1]. The most common manifestations of the disease involving the respiratory system are cough and shortness of breath, which can progress to respiratory distress and worsen the patient's status, necessitating mechanical ventilation. In some patients, it can involve other organs such as the heart, GI, owing to the broad distribution of the receptors of SARS-CoV-2 in the body [2, 3].

This case report presents a teenage boy with no past history of adrenal disease or cardiac problems who experienced these two manifestations following COVID-19

\*Correspondence: eskandari.d@iums.ac.ir

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, wisit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

infection. Many studies have reported cases of adrenal insufficiency due to COVID-19 severe sepsis, trauma, burns and pancreatitis. Also, some studies have described the association of COVID-19 and different autoimmune conditions such as Guillain-Barre syndrome, immune thrombocytopenic purpura, autoimmune hemolytic anemia, Kawasaki disease, and autoimmune thyroid disease [4]; however, Addison's disease and the production of antibodies against the adrenal glands after viral infections like COVID-19 is extremely rare, making this case unique. Because of limited sources and knowledge about rare manifestations of COVID-19, its mechanism is still unknown. The uncontrolled production of antibodies against the adrenal glands, which leads to self-destruction of the glands, might be resulted from an imbalance between the immune system and the related suppressor mechanism. In severe cases of COVID-19, the cytokine storm may be the trigger as well. Herein, we report a teenage boy who presented with various common and rare manifestations of COVID-19.

<sup>&</sup>lt;sup>1</sup> Department of Endocrinology, Rasool Akram Medical Complex, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

## **Case presentation**

An 18-year-old boy was admitted to the Rasool Akram Medical Complex on July 20,2020 complaining of shortness of breath, cough, nausea, vomiting, diarrhea and weakness.

As a routine assessment, the SARS-COV-2 RT-PCR (Reverse-Transcription Polymerase Chain Reaction) test was performed which its result was positive. On admission, some other tests were requested to evaluate the patients' status that their results have been shown in the Table 1. The patient was admitted to the COVID-19 ward and treated with a sofosbuvir and hydroxychloroquine regimen. A few days later, his respiratory status worsened and he was intubated and then treated with steroids and remdesivir. Ten days later, his condition improved, so he was extubated and discharged from the hospital. After 2 weeks, he was referred back to the hospital because of severe weakness, acute chest pain, and ECG abnormalities. His left ventricular ejection fraction (LVEF) was around 30% on echocardiography, accompanied with global hypokinesia. Due to typical acute chest pain and ECG, coronary angiography was performed that found to be normal.

During the first days of the admission, his blood pressure was 80/40 mmHg not responding to fluid resuscitation. His other symptoms worsened since his first admission. He complained of severe abdominal cramps, ongoing watery diarrhea, headache, and was so weak that he could not to walk unaided.

In the evaluation of his laboratory results, hyponatremia and resistant hyperkalemia were detected (Tables 2 and 3).

Table 1 Lab data on admission

Reference range
Less than 6 mg/L
Less than 15 mm/h
24–336 µg/L
100–250 ng/mL

Table 3	Hormone	levels	before	starting	hydrocortisone	and
fludrocortisone						

Hormone	Value	Reference range		
Cortisol 8a.m	1.4	9.3–25 µg/dl		
ACTH	>1800	7.1–56.3 pg/ml		
TSH	2.1	0.4–6.1 mIU/L		
T4	5.6	4.5–12.5 µg/dl		

Moreover, fluid resuscitation, respiratory support, thrombotic prophylaxis, and low dose aspirin (81 mg daily) were considered for him.

More specialized tests were conducted to make a more accurate diagnosis based on his symptoms, laboratory results, and suspicion of adrenal insufficiency. We detected an 8 am serum cortisol level of 1.8 (reference value:  $9.3-25 \mu g/dl$ ) and ACTH level of >1800 (reference value: 7.1-56.3 pg/ml). The high dose ACTH stimulation test (250 µg intravenous bolus) raised plasma cortisol value from the base level of 1.8 µg/dl to 10.2 µg/dl after 60 min which confirmed the diagnosis of adrenal insufficiency.

After administering 100 mg of intravenous hydrocortisone, the blood pressure increased, nausea and vomiting and abdominal pain disappeared. Also, the level of electrolytes returned to normal after a few hours. The treatment was continued with 300 mg of intravenous hydrocortisone daily (divided doses). The prescribed amount was reduced to 200 mg daily on the third day. On the fifth day, hydrocortisone was replaced by prednisolone and fludrocortisone (Fig. 1).

We also checked the level of 21-alpha hydroxylase antibodies, which indicated the diagnosis of Addison's disease. Interestingly, the patient had no evidence of skin or mucosa hyperpigmentation.

The follow-up with echocardiography (eco) after one month showed a significant improvement in LVEF–received from 30% in the last echo to 50% in the next echo. The effects of the treatments on decreasing the cardiac chamber size were also significant.

Table 2 lab data during hospitalization. Note the significant change in electrolyte after treatment

Parameter	Before	Day 1	Day 2	Day 3	Day 4	Reference value	
Sodium	129	130	132	140	135	135–145 mmol/L	
Potassium	6.2	6.2	6.5	5.4	4.8	3.7–5.5 mmol/L	
Creatinine	2.2	1.7	1.7	1.8	1.4	0.5–1.5 mg/dl	
WBC	3.1	2.9	2.6	2.9	3.3	$4-10 \times 10^{3}/\mu L$	
Hb	8.7	8.3	8.9	9	9	14–18 gr/dl	
Platelet	150	167	205	254	213	$140-440 \times 10^{6}/\mu L$	



# **Discussion and conclusion**

Recently published studies have revealed that myocardial damage caused by COVID-19 infection is not rare [5–8]. Zeng et al. reported a 63-year-old male who was admitted with an increased troponin I and general cardiac dyskinesia associated with a decreased LVEF, diagnosed as fulminant viral myocarditis [8]. Elevation of cardiac biomarkers level seems to be associated with a worse prognosis, requiring ICU admission and having a higher risk of sudden deaths in the cases infected with COVID-19 [9, 10].

The mechanism by which viral infections effects on cardiac function is still unknown. However, an elevated systemic inflammatory response and direct infection of the myocardial cells with viral replication can lead to general cardiac stress and isolated cell necrosis in various cardiac regions [11, 12].

In this study, we report a patient with confirmed COVID-19 pneumonia admitted with acute myocarditis and primary adrenal insufficiency.

Based on the studies, different pathogenic microorganisms can damage adrenal structure and function and should be considered as important [13].

Autopsy examination of cases died with SARS-CoV-1 infection revealed that adrenal necrosis with monocytes and lymphocytic infiltration can lead to vasculitis of small veins in the adrenal glands [14, 15]. Additionally, it is speculated that the direct cytopathologic effects of SARS-CoV-2 on adrenal tissue are the result of the high expression of ACE2 (the angiotensin converting enzyme-2) and TMPRSS2 (encoding transmembrane protease serine 2) in the adrenal glands [16, 17]. Hashim et al. reported a case of a 51-year-old male admitted with a history of frequent occurrence of vomiting. On clinical examination, low blood pressure (88/58 mmHg), hypona-tremia (sodium 108 mmol/L) and hypochloremia (chloride 78 mmol/L) were detected. Eventually, low morning cortisol level (127 nmol/L) and ACTH stimulation testing confirmed the presence of adrenal insufficiency. Starting a 20 mg daily dose of prednisolone increased the blood pressure and sodium level of the patient [13].

Although clinical features such as pigmentation refer to chronic adrenal insufficiency, lack of it may be in favor of an acute event. However, we agree that there is definite discordance between adrenal imaging and clinical features. In our finding, enlarged adrenal glands with fat stranding in the suprarenal space in COVID-19 related acute adrenal necrosis were shown. This growth can be due to inflammation, a reactive increase in blood flow, and congestion. Small hemorrhagic foci can result in the morphologic changes as well. More specific imaging features of adrenal infarct, such as capsular sign have been described in CT exploration realized at the portal venous phase [18].

It should be considered as important that viral infections can cause multiple organic damages, including cardiac and adrenal injury as our study shown. To the best of our knowledge, this is the first reported case of the adrenal insufficiency with myocarditis following COVID-19 infection. In conclusion, the high clinical suspicion of the primary adrenal insufficiency should be considered in critically ill COVID-19 patients, especially in those with hypotension unresponsive to fluid therapy, hyponatremia and hyperkalemia. Additional information about the underlying mechanism needs further investigation and brainstorming among all medical centers to make an exact and timely diagnosis for better management of this crucial situation.

# Limitation

While this is an intriguing theory that COVID-19 may be capable of causing Addison's disease, this case does not establish definitive causation, and early Addison's disease could also simply have been triggered by severe stress, as shown in this case report. Adrenal atrophy is odd with an acute event, although calcification is nonspecific. As we mentioned earlier, positive adrenal autoantibodies suggest autoimmune adrenalitis. Our case is probably an unmasking of an acute adrenal crisis in the background of subclinical adrenal insufficiency due to an autoimmune process. Delayed onset myocarditis after two weeks of original presentation along with raised inflammatory markers suggests post COVID-19 multisystem inflammatory syndrome (MIS-A) rather than acute myocarditis, but RT-PCR was positive during this presentation [19].

Acute myocarditis due to direct viral cytopathic effects on myocardium. RT-PCR positivity is not odd after 2 weeks, and not against MIS-A [19].

#### Abbreviations

GI: GastroIntestinal; SARS-CoV-2: SevereAcute Respiratory Syndrome Coronavirus 2; COVID-19: coronavirusdisease-19; LVEF: LeftVentricular Ejection Fraction; ECG: ElectroCardio Gram; MIS-A: MultiSystem Inflammatory disorder \_in adults; ACE2: theangiotensin converting enzyme-2; TMPRSS2: encodingtransmembrane protease serine 2.

# **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s12902-022-01257-3.

# Additional file 1.

Additional file 2.

## Acknowledgements

We would like to show our gratitude to the Rasool Akram Medical Complex Clinical Research Development Center (RCRDC) specially Mrs Farahnaz Nikkhah for their technical and editorial assists.

#### Authors' contributions

DE had made substantial contributions to the conception, DE and AAA contributed to study design; AT and MMJM collected the data; EZ and AT analyzed the data; AAA prepared the manuscript, DE and AZ did critical revision of the manuscript; and all authors read and approved the final version for submission.

#### Funding None.

None.

## Availability of data and materials

The data used to support the findings of this study are included within the article.

# Declarations

# Ethics approval and consent to participate

Not applicable.

## **Consent for publication**

Written informed consent was obtained for the publication of this case report. a copy of the consent form is available for the Editor to review upon request. Moreover, the patient gave written consent for his personal or clinical details to be published in this study.

## **Competing interests**

The author reports no conflicts of interest in this work.

#### Author details

<sup>1</sup>Department of Endocrinology, Rasool Akram Medical Complex, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. <sup>2</sup>Department of Cardiology, Rasool Akram Medical Complex, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Internal Medicine, Rasool Akram Medical Complex, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Received: 1 June 2021 Accepted: 16 December 2022 Published online: 31 December 2022

## References

- World Health Organization. Published 2021. Accessed June 1. https://www.who.int/publications/m/item/weekly-epidemiolo gical-update-on-covid-19---1-june-2021.
- Pormohammad A, Ghorbani S, Baradaran B, Khatami A, Turner RJ, Mansournia MA, et al. Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: a systematic review and meta-analysis. Microb Pathog. 2020;147:104390.
- Stein RA, Young LM. From ACE2 to COVID-19: a multiorgan endothelial disease. Int J Infect Dis. 2020;100:425–30.
- Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2021;J Med Virol.
- Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(2):206-.
- Khalid N, Chen Y, Case BC, Shlofmitz E, Wermers JP, Rogers T, et al. COVID-19 (SARS-Cov-2) and the heart–an ominous association. Cardiovascr Revascn Med. 2020;21(8):946–9.
- Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10.
- Zeng J-H, Liu Y-X, Yuan J, Wang F-X, Wu W-B, Li J-X, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48(5):773–7.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA Cardiol. 2020;323(11):1061–9.
- Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res. 2020;126(10):1443–55.
- Yao X, Li T, He Z, Ping Y, Liu H, Yu S, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin J Patholy. 2020;49:E009-E.

- Hashim M, Athar S, Gaba WH. New onset adrenal insufficiency in a patient with COVID-19. BMJ Case Rep. 2021;14(1):e237690.
- Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–9.
- Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–47.
- Mao Y, Xu B, Guan W, Xu D, Li F, Ren R, et al. The adrenal cortex, an underestimated site of SARS-CoV-2 infection. Front Endocrinol (Lausanne). 2021;11:1060.
- Wong DW, Klinkhammer BM, Djudjaj S, Villwock S, Timm MC, Buhl EM, et al. Multisystemic cellular tropism of SARS-CoV-2 in autopsies of COVID-19 patients. Cells. 2021;10(8):1900.
- Leyendecker P, Ritter S, Riou M, Wackenthaler A, Meziani F, Roy C, et al. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-COV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol. 2021;31(2):895–900.
- Bajaj R, Sinclair HC, Patel K, Low B, Pericao A, Manisty C, et al. Delayed-onset myocarditis following COVID-19. Lancet Respir Med. 2021;9(4):e32–4.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

